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The importance of immune dysfunction in determining outcome
in acute liver failureq
Charalambos Gustav Antoniades*, Philip A. Berry, Julia A. Wendon+, Diego Vergani+
Institute of Liver Studies, King’s College Hospital, Denmark Hill, London SE5 9RS, UKAcute liver failure (ALF) shares striking similarities with septic shock with regard to the features of systemic inﬂam-
mation, progression to multiple organ dysfunction and functional immunoparesis. While the existence of opposing systemic
pro- and anti-inﬂammatory proﬁles resulting in organ failure and immune dysfunction are well recognised in septic shock,
characterization of these processes in ALF has only recently been described. This review explores the evolution of the sys-
temic inﬂammation in acute liver failure, its relation to disease progression, exacerbation of liver injury and development of
innate immune dysfunction and extra-hepatic organ failure as sequelae. Defects in innate immunity are described in hepatic
and extra-hepatic compartments. Clinical studies measuring levels of pro- and anti-inﬂammatory cytokines and expression
of the antigen presentation molecule HLA-DR on monocytes, in combination with ex-vivo experiments, demonstrate that
the persistence of a compensatory anti-inﬂammatory response syndrome, leading to functional monocyte deactivation, is a
central event in the evolution of systemic immune dysfunction. Accurate immune proﬁling in ALF may permit the devel-
opment of immunomodulatory strategies in order to improve outcome in this condition.
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Acute liver failure (ALF) is a clinical syndrome charac-
terized by peripheral vasodilatation, encephalopathy and
coagulopathy culminating in multiple organ dysfunction
syndrome (MODS) and death. There is increasing evi-
dence that activation of systemic immune responses plays
apivotal role in its pathogenesis andoutcome.Large stud-
ies demonstrate that the presence of the systemic inﬂam-
matory response syndrome (SIRS) in ALF is associated
with aworsening of encephalopathy and a poor prognosis0168-8278 Crown copyright  2008 Published by Elsevier B.V. on behalf of
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Open access under CC BY-NC-ND license.[1,2]. Trewby et al. initially recognised that the haemody-
namic proﬁle in ALF mirrors that of septic shock [3].
Although these two conditions are distinct disease enti-
ties, their striking phenotypic similarity implies that they
may also share pathogenic mechanisms such as uncon-
trolled activation of the systemic inﬂammatory cascade
responsible for the transition from SIRS to refractory
MODS. This review focuses on the immunological alter-
ations identiﬁed in ALF with particular emphasis on the
association between SIRS, progressive MODS, hepato-
cyte death, and systemic immune dysfunction.2. The importance of SIRS, MODS and sepsis in acute
liver failure
There is substantial evidence that SIRS contributes to
morbidity and mortality in ALF, with MODS and
complicating sepsis being signiﬁcant sequelae. In athe European Association for the study of the liver.
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association of infection with progression of encephalop-
athy through activation of SIRS, with attendant poor
prognosis [1]. Subsequently, Vaquero et al. reporting
the experience of the US ALF group [2], noted that in
acetaminophen-induced ALF, the progression of
encephalopathy was signiﬁcantly more frequent in the
presence of infection than in its absence. Of note, both
studies went on to show that SIRS, independent of
infection, is associated with worsening of the encepha-
lopathy score and a poorer prognosis. A recent report
by Schmidt and Larsen [4] conﬁrmed that the presence
of SIRS in ALF carries a poor prognosis and also iden-
tiﬁed correlations between composite organ failure
scores (SOFA), disease severity and SIRS components.
Rolando et al. identiﬁed the importance of infection in
ALF in 1990, documenting frequencies between 50%
and 90% [1,2,5]. Infection develops early in the course
of ALF, with a median onset time of 2–5 days following
admission to hospital [6], and is responsible for late
death in at least a quarter of cases [5]. The relatively
recent introduction of corticosteroids in the treatment
of functional adrenal insuﬃciency associated with circu-
latory shock in ALF [7,8], may further increase suscep-
tibility to infections. Despite improvement in medical
care and routine use of prophylactic antibiotics, sepsis
remains a major cause of mortality in ALF.3. SIRS and evolution to MODS
SIRS is the clinical expression of an abnormal gener-
alised inﬂammatory reaction in organs distant from the
initiating insult. This term, originally coined by Bone et
al., deﬁnes: ‘‘the systemic inﬂammatory response to a
variety of severe clinical insults, manifested by two or
more of the following conditions: (1) temperature
>38 C or <36 C; (2) heart rate >90 beats/min; (3)
respiratory rate >20 breaths/min or PaCO2 <32 mm Hg
(<4.3 kPa); (4) WBC count >12,000/mm3, <4000/mm3,
or >10% immature (band) forms” [9,10]. The deﬁnition
is adopted to describe systemic inﬂammation as [9,10]
consequence of infection, comprising a strictly linked
sequence of pathological states from sepsis to septic
shock. Other conditions associated with a systemic
inﬂammatory response include polytrauma, major sur-
gery, severe burns and pancreatitis [11–16]. There is con-
siderable evidence showing that the severity of SIRS
correlates with the severity of organ dysfunction and
mortality rate [12,16,17]. Over the past decade, studies
have shown that the inﬂammatory reaction constituting
SIRS is characterized by the elevation of circulating lev-
els of both pro- (TNF-a, IL-1, IL-6) [18–21] and anti-
inﬂammatory cytokines (IL-10) [22–24]. The magnitude
of increase of both of these functionally opposing sets of
cytokines strongly correlates with severity of organ fail-ure and mortality [18,22]. A sequence of events linking
the initial inﬂammatory insult to subsequent MODS
and immune dysfunction has been postulated.
3.1. Local inﬂammatory response
Local tissue injury or invading microbial agents trig-
ger local mediators of innate immunity to release an
array of pro-inﬂammatory mediators through the acti-
vation of macrophages, polymorphonuclear phagocytes,
endothelial cells and the complement system. This acti-
vation leads to elimination of pathogens, with attendant
damage to tissue, but also promotes tissue regeneration
[11,25].
3.2. Systemic pro-inﬂammatory response
Chemotactic mediator release and endothelial cell
activation serve to recruit circulating immune eﬀector
cells (monocytes, lymphocytes), augmenting the local
immune response to injury/infection [11,13]. Systemic
inﬂammation occurs following intravascular ‘‘spill over”
of local inﬂammatory mediators generated at the site of
injury/infection. Pro-inﬂammatory cytokines recruit fur-
ther circulating neutrophils, B and T cells and increase
vascular permeability by activating vasoactive media-
tors, platelets and the coagulation cascade.
3.3. Compensatory anti-inﬂammatory response syndrome
(CARS)
A rise in the circulating levels of anti-inﬂammatory
cytokine and mediators in response to systemic pro-
inﬂammatory cytokine release represents a counter-reg-
ulatory homeostatic mechanism aimed at preventing
overwhelming inﬂammation. This is termed the compen-
satory anti-inﬂammatory response syndrome (CARS)
and is deﬁned by persistently elevated circulating levels
of anti-inﬂammatory cytokines (IL-4, -10, transforming
growth factor [TGF]-b), and by impairment in cellular
immune function. This is demonstrable in phenotypic
and functional changes that occur in monocytes, result-
ing in monocyte deactivation, an event central to the
development and evolution of CARS. Here a decrease
in pro-inﬂammatory cytokine secretion is accompanied
by loss of antigen presenting capability, while produc-
tion of IL-10 is not only preserved but increased. The
point of transition from a homeostatic response to the
pathological state of CARS, characterized by ‘‘exces-
sive” immunosuppression and increased predisposition
to infection, has not been clearly deﬁned.
3.4. Immunological dissonance
This phase represents the persistence of an ‘‘unbal-
anced” inﬂammatory response that results in refractory
Pro-inflammatory
response
Anti-inflammatory
reponse
CARS
Immuno-
homeostasis
Excess pro-inflammatory: early mortality
SIRS
Persistent CARS:
Recurrent sepsis//MODS
Fig. 1. Interaction between the pro-(SIRS) and anti-inﬂammatory responses (CARS) in the evolution of the systemic inﬂammatory response in sepsis
(adapted from Kox et al. [25]). Predominance of either a pro- or anti-inﬂammatory response may result in loss of immunohomeostasis and death. If the
initial pro-inﬂammatory response is overwhelming (blue dotted line) then the host may succumb early with overwhelming inﬂammation (red dotted line).
Death later in the course of disease (red dotted line) can occur as a consequence of persistence in the anti-inﬂammatory response (solid black line). SIRS
systemic inﬂammatory response syndrome. CARS compensatory anti-inﬂammatory response syndrome. MODS multiple organ dysfunction syndrome.
C.G. Antoniades et al. / Journal of Hepatology 49 (2008) 845–861 847multiple organ failure and increased risk of death. While
an excessive SIRS accounts for the early mortality in
patients with septic shock [26,27], the late mortality in
refractory septic shock is most likely due to persistent
CARS [28]. Here abrogation of pro-inﬂammatory cyto-
kine production and monocyte deactivation prevent
clearance of infection and recovery from organ failure
(Fig. 1). The clinical sequelae of monocyte deactivation
will be discussed in more detail.4. The central role of monocytes in SIRS and CARS
Monocytes/macrophages are central to both innate
and adaptive arms of the immune responses (Fig. 2). Fol-
lowing the binding ofmicrobial constituents (such as lipo-
polysaccharide (LPS) and cell wall constituents of Gram-
positive bacteria) to complementary receptors on the cell
surface of monocytes/macrophages, large amounts of
both pro- and anti-inﬂammatory cytokines are produced.
In addition to being activated after exposure to non-spe-
ciﬁcmicrobial stimuli,monocytes have, in turn, the ability
to trigger adaptive immune responses. After enzymatic
digestion and processing, they express [12–18] amino acid
long peptides from these digested antigens on their cell
surface within the groove of an HLA class II molecule,
typicallyHLA-DR.This peptide/HLAmolecule complex
present on the monocytes can activate T lymphocytes in a
very speciﬁc manner, through ligation to the complemen-
tary T cell receptor molecule and, in the presence of
appropriate co-stimuli, T cells become activated and set
in motion an adaptive immune response.
Endotoxin tolerance has been described in experi-
mental animal models where repeated exposure to endo-toxin (LPS) [29] induces qualitative and quantitative
alterations in monocyte function, particularly in inﬂam-
matory cytokine production and surface expression of
HLA class II antigens (Fig. 3). Following repetitive
LPS challenge, there is an alteration in inﬂammatory
mediator secretion with an attenuated pro-inﬂammatory
[30–32] and enhanced anti-inﬂammatory cytokine [33–
35] secretion proﬁle. Endotoxin tolerance induces
reduced surface expression of the antigen presenting
HLA class II molecules, impairing the ability of these
cells to induce T cell responses following antigenic stim-
ulation [35]. Exposure to a wide range of mediators such
as lipoteichoic acid, peptidoglycan, bacterial lipopro-
tein, catecholamines [36,37], glucocorticoids [38–43]
and IL-10 [29] can also induce a state comparable to
endotoxin tolerance.
There is considerable evidence to indicate a role for
monocyte ‘‘dysregulation” as part of CARS in condi-
tions previously identiﬁed as uniquely due to SIRS.
Ex-vivo studies of monocytes from patients with septic
shock, show a profound reduction in HLA-DR expres-
sion associated with reduced production of pro-inﬂam-
matory cytokines (TNF-a, IL-1, IL-6) [28,34] and
augmented production of IL-10 [34] following stimula-
tion with LPS. This ﬁnding has been linked with a high
incidence of superimposed infections and poor clinical
outcome. Numerous clinical studies have assessed
monocyte HLA-DR expression as a phenotypic marker
of functional monocyte deactivation. A profound reduc-
tion in monocyte HLA-DR expression is a consistent
ﬁnding, present in septic shock [41,44–48], trauma and
post operative patients [48–52]. Secondly, HLA-DR lev-
els are consistently lower in non-survivors than in survi-
vors [48,50]; survival being associated with recovery to
LPS 
LPS- binding protein 
+ 
CD14, TLR-2/-4 
LPS receptors 
Mono/mϕ 
Innate immunity 
TNF-α, IL-1, IL-6, IL-10 
Coagulation 
cascade 
Prostaglandins 
leukotrienes
Complement 
cascade
Nϕ activation 
Adaptive immunity 
CD4+/T cell 
Endothelial cell 
activation/damage 
Multiple organ 
dysfunction/failure 
Specific anti-microbial 
immunity
(Th1/Th2 responses) Activated 
mono/m
HLA class II
augmented
Fig. 2. Schematic representation of the role of monocytes/macrophages in the activation of inﬂammatory responses following the encounter with microbes
and microbial products. Lipopolysaccharide (LPS) is released from Gram-negative bacteria and forms a complex with LPS binding protein. Interaction
with cell surface receptor, CD14, on monocytes/macrophages (mono/mu) and toll-like receptors (TLR-2/4) activates the production of NF-jB inducible
inﬂammatory cytokines. Monocyte and neutrophil (nu) engagement results in the activation of the systemic inﬂammatory cascade, and this, if
uncontrolled, leads to multiple organ dysfunction syndrome (MODS). Monocyte activation also triggers adaptive immune responses via its antigen
presentation capabilities (MHC class II expression) to CD4+ helper T cells whose engagement leads to an orchestrated immune response capable of
eliminating the microbial organism.
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monocyte deactivation is a dynamic event, varying
through the evolution of systemic inﬂammatory
responses and directly inﬂuencing outcome in these
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to the concept of an initial pro-inﬂammatory followed
by an anti-inﬂammatory response, these functionally
opposing processes occur simultaneously, though over
time the balance may be tilted towards an anti-inﬂam-
matory response. In murine polymicrobial sepsis, ele-
vated levels of pro-inﬂammatory (TNF-a, IL-1b, IL-6,
chemokines) and anti-inﬂammatory (TNF soluble
receptors, IL-1 receptor antagonists, IL-10) mediators
are detected within six hours of onset of sepsis [53],
conﬁrming earlier reports that following endotoxin
exposure an early TNF-a secretion is soon matched by
IL-10 release [54,55].
A considerable amount of interest in the anti-inﬂam-
matory role of IL-10 in systemic inﬂammatory responses
has stemmed from its ability to induce monocyte deacti-
vation in in vitro and in vivo studies [35,57]. Experimen-
tal models of endotoxaemia and human studies of sepsis
have documented a biphasic response to IL-10 secretion,
where an early rise is paralleled by release of pro-inﬂam-
matory mediators [53,54,58]. The second peak in IL-10
occurs in the later stages of endotoxaemia and is associ-
ated with monocyte deactivation and poor outcome
[56,58,59]. Hepatic macrophages have been implicated
as the main source of the late IL-10 peak [54]. Elevations
in circulating TGF-b levels have also been described in
patients with SIRS [58,60]. There is no evidence, how-
ever, indicating a pathogenic role of TGF-b in CARS.
The observation that TGF-b can suppress monocyte
function warrants further investigation [61,62].
The anti-inﬂammatory properties of cyclopentenone
prostaglandins (cyPGs) have also been described in ani-
mal models of endotoxaemia and sepsis [62–65]. These
studies reveal that the anti-inﬂammatory eﬀects are
mediated through inhibition of IKK-b/NF-jB depen-
dent pro-inﬂammatory gene transcription [66], induc-
tion of anti-inﬂammatory proteins (heat shock protein
70, haeme oxygenase-1) [64] and apoptosis [63]. Recent
work supports the role of these anti-inﬂammatory medi-
ators in the resolution of inﬂammation through inhibi-
tion of pro-inﬂammatory mediator release and
promotion of apoptosis of activated macrophages
[67,68]. Further work may better deﬁne the role of cyP-
Gs in systemic inﬂammatory responses.6. ‘‘Systemic’’ immune defects in ALF
6.1. Monocyte dysfunction
In light of the alterations of monocyte phenotype and
function in septic shock, monocyte studies have been
conducted in ALF. Despite a marked SIRS, implying
a major role for monocytes, only a few studies have
investigated relationships between the functional state
of circulating monocytes with the proﬁle and degree ofinﬂammatory mediator production in ALF [69–71]. In
patients with acetaminophen-induced ALF, circulating
monocytes have reduced ability to secrete TNF-a fol-
lowing endotoxin challenge when compared to healthy
controls [69,70]. This impaired secretion, possibly
reﬂecting monocyte exhaustion, is associated with poor
outcome.
The King’s College group evaluated monocyte TNF-a
expression in a cohort of ALF patients, ﬁnding high levels
of monocyte TNF-a expression in comparison to patho-
logical and healthy controls [72]. Furthermore, monocyte
TNF-a expression strongly correlated with circulating
levels of the cytokine, suggesting that monocytes are an
important source of its enhanced production. However
this work does not provide dynamic information on
monocyte function during the evolution of ALF. By
quantiﬁcation of cytokine production following LPS
challenge, we have recently demonstrated endotoxin tol-
erance inmonocytes from patients with ALF. Thus, while
there is no signiﬁcant increase in TNF-a secretion upon
endotoxin stimulation, a signiﬁcant rise in IL-10 secretion
is seen [73]. This ﬁnding, novel in ALF, supports the con-
cept of a shift towards amonocyte anti-inﬂammatory pro-
ﬁle in the progression of ALF.
IL-10 is a pleiotropic cytokine with well characterized
anti-inﬂammatory and immunosuppressive properties. A
subset of IL-10 producing monocytes, described in
patients with ovarian carcinoma, inhibits T cell prolifera-
tion andTh1 type cytokine production [74]. In addition to
producing IL-10, these cells have low HLA-DR expres-
sion and consequently reduced antigenpresentation capa-
bilities. In a recent publication we highlight the value of
assessing monocyte deactivation in monitoring the sever-
ity of acute hepatic injury and predicting adverse outcome
in ALF. The main ﬁnding is a marked reduction in HLA-
DRexpression on the surface of circulatingmonocytes – a
sign of functional monocyte deactivation in parallel with
increased serum levels of IL-10 [71]. This observation is
reminiscent of that in septic shock where it was ﬁrst
described. Reduced monocyte HLA-DR expression and
the inability to recover its expression are shown to be pre-
dictors of poor prognosis and also parallel disease sever-
ity. Collectively, these studies provide evidence that a
systemic compensatory anti-inﬂammatory response,
accounting for a grossly impaired HLA-DR expression
on monocytes, is present in ALF.
Given the strong relationship that has been demon-
strated between high levels of circulating IL-10, low
monocyte HLA-DR expression and poor clinical out-
come in ALF [71], we suggest a role for a phenotypically
similar monocyte population. Thus we found a 7- to 16-
fold expansion in IL-10 producing monocytes in ALF
patients compared to pathological and healthy controls
[72]. Furthermore, ex-vivo experiments show a marked
reduction in IFN-c evoked responses to a panel of com-
mon recall antigens, indicating an impairment in antigen
850 C.G. Antoniades et al. / Journal of Hepatology 49 (2008) 845–861presentation capabilities [73]. A possible mechanism for
progression to functional monocyte deactivation during
systemic inﬂammatory responses in ALF is illustrated in
Fig. 4. This shows the critical steps from acute liver
injury to systemic immune dysfunction mediated by
IL-10 and its eﬀect on monocyte function, thus render-
ing the patient vulnerable to sepsis, MODS and death.
6.2. Complement
Several defects of innate immunity in ALF aﬀecting
the complement system, neutrophil and Kupﬀer cell
function have been demonstrated. The liver is the major
site of complement synthesis, and reductions in serum
complement levels and functional activity were identi-
ﬁed over 20 years ago [75]. ALF patients have qualita-
tive and quantitative changes in both classical and
alternative complement pathways; well documented
are the defects of C3, C5 and CH50 [75–78]. In vitro
studies have shown that serum from ALF patients deﬁ-
cient in C3 and C5, has reduced opsonic capacity against
Escherichia coli and yeasts [75], and poor chemoattrac-
tant ability for neutrophils [76].Fig. 4. Proposed mechanism of functional monocyte deactivation during the
production by Kupﬀer cells, followed by inﬂammatory cell recruitment, which e
cytokines triggers the systemic inﬂammatory response including monocyte act
both pro-(TNF-a, IL-1, IL-6) and anti-(IL-10) inﬂammatory cytokines. The pre
of the inﬂammatory response (SIRS). However, the systemic spill-over resultin
damaging eﬀect of pro-inﬂammatory cytokines, leads to severe inhibition of H
(CARS – compensatory anti-inﬂammatory response syndrome). This results in
responses. If the hepatic inﬂammatory insult remains uncontrolled, persistent f
immunoparesis, namely recurrent infections and ultimately refractory multiple6.3. Neutrophils
Through a series of ex-vivo studies, Rolando et al.
demonstrated that neutrophils are also functionally
impaired in ALF. Reductions in superoxide/hydrogen
peroxide production [78,79], phagocytosis/intracellular
killing capacity and complement receptor expression
[79] were identiﬁed. Exposure to exogenous granulocyte
colony-stimulating factor (G-CSF) improved neutrophil
phagocytic and killing capacities in both in vivo and
in vitro experiments [79,80]. Given its ability to reverse
defective neutrophil function, the administration of G-
CSF has been considered for restoring immune
responses in an eﬀort to reduce the incidence of infection
in ALF. Large prospective studies are required to eval-
uate this possibility.
6.4. Fibronectin
Plasma ﬁbronectin is a hepatically synthesised glyco-
protein that aids the clearance of circulating microbes
and microbial products through their opsonisation and
subsequent microbial uptake and clearance by Kupﬀer
and other cells of the reticuloendothelial system (RES).evolution of acute liver failure. Acute liver injury stimulates TNF-a
xacerbates the initial liver injury. Systemic ‘‘spill-over” of inﬂammatory
ivation. Following initial activation, monocytes secrete large amounts of
dominant cytokine secretion proﬁle is pro-inﬂammatory at an early stage
g in high circulating levels of IL-10, initially secreted to counteract the
LA-DR expression on monocytes and functional monocyte deactivation
inability of CD4+ T cells to orchestrate cellular and humoral immune
unctional monocyte deactivation ensues with attendant manifestations of
organ dysfunction syndrome (MODS).
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edly reduced in ALF. Studies in man have shown a corre-
lation between low serum ﬁbronectin concentration and
impaired Kupﬀer cell function, as documented by the
low systemic clearance of microaggregated albumin [81],
and by an increased predisposition to infection and a
higher mortality rate [82,83].7. The inﬂammatory cytokine cascade following acute
liver injury
Human studies have provided insights into the delete-
rious eﬀects of cytokines with regard to the severity of
circulatory dysfunction and organ failure. However,
most data supporting a pathogenic role for inﬂamma-
tory cytokines are derived from animal models. It is
helpful to consider these cytokines as part of a compart-
mental model.
7.1. Hepatic compartment
TNF-a plays a critical role in the pathogenesis of hepa-
tic injury through activation of pro-apoptotic pathways
(see below). Although the monokine IL-6 is likened to
TNF-a in systemic inﬂammatory processes, acting syner-
gistically in generating the acute phase response, their
respective roles diverge in acute liver injury. IL-6 prevents
liver injury inmurinemodels ofALF through its ability to
down-regulate TNF-aproduction [84].Numerous studies
have also shown the pivotal role of this cytokine in hepatic
regenerative responses following partial hepatectomy and
in experimental ALF models [85,86].
In the experimental animal, there is good evidence that
the anti-inﬂammatory response, characterized by IL-10
production, initially ameliorates acute liver injury. This
has been reported in numerous immune [87–94] and
non-immune [95] mediatedALFmodels through the abil-
ity of the cytokine to reduce the levels of pathogenic pro-
inﬂammatory cytokines, in particular TNF-a [91,92].
7.2. Systemic compartment
Table 1 summarises human studies evaluating circu-
lating inﬂammatory cytokine levels in ALF. Irrespective
of ALF aetiology, most studies report increased levels of
pro-inﬂammatory cytokines including TNF-a [70,71,94,
96–99], IL-1 [96,99,100], IL-6 [70,71,94,100,101] and
IL-8 [100]. Recent work from our unit has demonstrated
a strong relationship between circulating levels of pro-
inﬂammatory cytokines and the degree of vasodilatory
shock [100], vasopressor requirement and severity of
acute hepatic injury [71]. Given the parallel between lev-
els of circulating pro-inﬂammatory cytokines and degree
of systemic inﬂammation in ALF, a few studies suggest
that measuring pro-inﬂammatory cytokines may be ofvalue in discriminating survivors from non-survivors.
Early studies, based on small numbers of patients, have
shown that the levels of TNF-a and IL-6 are higher in
non-surviving than in surviving ALF patients
[94,98,100,101]. A large study from our institution, of
predominantly acetaminophen- induced ALF cases,
identiﬁed markedly higher circulating levels of TNF-a
and IL-6 in non-surviving or transplant-requiring ALF
patients compared to those who survived spontaneously
[71]. This indicates the value of soluble eﬀectors of
immune response as predictors of outcome. Their inclu-
sion into prognostic scoring systems should be evaluated.
Raised circulating levels of IL-10 have been recently
reported in ALF with viral and non-viral aetiology
[94,97]. Our group has found that levels of IL-10 are
not only increased in ALF but strongly correlate with
levels of pro-inﬂammatory cytokines and markers of
severity of acute hepatic injury [71]. These ﬁndings,
novel in the ALF setting, indicate that activation of
the systemic inﬂammatory process shares similarities
with other pathological states where a profound SIRS
is counterbalanced by a strong and persistent CARS
leading to systemic immune dysregulation and poor out-
come. Our data, those in the experimental animal and in
other clinical conditions, all support the role of CARS in
augmenting a predisposition to sepsis and refractory
MODS, a characteristic of end-stage ALF.8. Innate immunity and development of acute liver injury
The innate immune system is based on broadly spe-
ciﬁc recognition and eﬀector processes that do not
require the more specialised antigen recognition path-
ways of adaptive immune responses. The liver is a
unique organ that is rich in cellular eﬀectors of the
innate immunity, and studies have shown that these
are central to the process of hepatocellular injury.
8.1. Kupﬀer cells and macrophages
Kupﬀer cells (KC) exert a pivotal ‘‘ﬁltering” role over
microbes and microbial products carried via the portal
circulation. Early studies documented high circulating
levels of endotoxin in ALF suggesting impaired RES
activity [102,103]; defective KC function has been indi-
rectly demonstrated by reduced [125] I-labelled microag-
gregated albumin and galactose clearance [77,104]. The
degree of KC dysfunction reﬂects severity of liver injury,
and a return to normal function is observed in patients
who recover spontaneously.
KC and macrophages contribute to liver injury in a
wide spectrum of experimental models of acute liver fail-
ure [105–109]. In the non-inﬂamed liver, KC secrete
anti-inﬂammatory mediators, such as IL-10 [110,111],
Table 1
Summary of clinical studies investigating the of inﬂammatory cytokines in acute liver failure
Aetiology (# of patients) Serum cytokine measured Cytokine as outcome measure
IL-1 IL-6 TNF-a IL-10
Muto et al. [96] Viral (6)
AALF (5) " – " – No
Seroneg (5)
AALF (14)
De La Mata et al.[69] Viral (6) – – " (Viral ALF*) – Yes
Seroneg (5) ; (AALF*) Low TNF-a in non-surviving AALF*
Izumi et al. [101] AALF (40)
Viral/other (10) ; " – – Yes Higher IL-6 in non-survivors
Sekiyama et al. [99] Viral (30) " " " – Yes Higher IL-1 in non-survivors
Wigmore et al. [70] AALF (10) – " " – No
Seroneg (2)
Nagaki et al. [94] Viral (19) – ; " " Yes Higher TNF-a and IL-10 in non-survivors
Streetz et al. [98] Viral (8) – – " – Yes Higher TNF-a in non-survivors
Drug (5)
Amanita (4)
Other (5)
Sheron et al. [100] AALF (45) – "" "" – Yes Higher IL-6 in non- survivors
Seroneg (7)
Viral (3)
Other (6)
Yumoto et al. [97] Viral (14) – – – " Yes Higher Il-10 in survivors
Drug (4)
Seroneg (2)
Antoniades et al. [71] AALF (50) – "" " "" Yes Higher TNF-a, IL-6, IL-10 in non-survivors
Seroneg (5)
Viral (6)
Other (9)
Abbreviations for aetiologically distinct groups: Viral, ALF secondary to viral hepatitides; AALF, acetaminophen-induced ALF; Seroneg, ALF with
no identiﬁable aetiology; Amanita, amanita phalloides induced ALF.
* Peripheral blood mononuclear cell derived lipopolysaccharide-induced TNF-a production.
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ing exposure to pro-inﬂammatory mediators (LPS, bac-
terial DNA) derived from the portal circulation. The net
eﬀect of this exposure is a reduction in liver sinusoidal
endothelial (LSEC) adhesion molecule expression, anti-
gen uptake and presentation, and, consequently, reduc-
tion in T cell activation [114,115]. In the acutely
inﬂamed liver, the hepatic insult activates KC/macro-
phages to secrete copious amounts of pro-inﬂammatory
mediators. The contributory role of KC/macrophage-
derived cytokines (TNF-a [116–120], IFN-c [117,121–
123]), chemokines (MCP-1, IL-8 [124,125]), reactive
oxygen/nitrogen species [106] and expression of death
ligands in the process culminating in hepatocyte death
is well documented.
The LPS/ranitidine model of hepatotoxicity illus-
trates how KC may initiate and sustain acute liver
injury [126]. Liver injury is induced through co-treat-
ment of KC with low-dose LPS and ranitidine. In
isolation, neither of these agents induces hepatotoxic-
ity – while in combination they do – supporting the
notion of a critical ‘‘threshold” of KC activation
above which the release of inﬂammatory mediators
causes liver injury. TNF-a is the key mediator ofhepatocyte death acting through both direct and indi-
rect mechanisms (Fig. 5). In ALF, however, these
cells, have also been shown to secrete cytokines (IL-
6, -10, -18) that compensate the deleterious eﬀects
of the pro-inﬂammatory response [95,127,128]. A
homeostatic counter-regulatory process is therefore
operating in acute liver injury aimed at oﬀsetting
the damaging eﬀects of unhindered pro-inﬂammatory
KC/macrophage activation.
8.2. Natural killer (NK) and natural killer T cells (NKT)
NK and NKT cells are another major cellular com-
ponent of innate immunity, much more abundant in
the liver than in lymphoid organs and peripheral blood
[114]. The roles of NK/NKT cells in the progression of
liver injury are described in acetaminophen [129] and
Con-A ALF [130] models. Upon stimulation, NK/
NKT cells release large amounts of IL-4, IL-5 and espe-
cially IFN-c, which participate in liver injury through
induction of hepatocyte apoptosis [121,123], chemokine
production [122,129], LSEC adhesion molecule expres-
sion [122], activation/recruitment of other immune eﬀec-
tor cells [129,131]. NK and NKT cells also directly
TNF-α
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Fig. 5. Role of Kupﬀer cells and inﬁltrating macrophages in the initiation and propagation of acute liver injury. Following Kupﬀer cell (KC) and
macrophage (mu) activation by a noxious stimulus (e.g. lipopolysaccharide [LPS], unmethylated CpG motifs of bacterial DNA [CpG]) hepatocyte death
is induced by both direct and indirect mechanisms. Hepatocyte apoptosis can occur through the direct interaction of TNF-a and Fas ligand (FasL) with
their respective ligands on hepatocytes. Indirect mechanisms of hepatocyte death occur through TNF-a induced activation of liver sinusoidal endothelial
cell (LSEC). Platelet activation, sinusoidal ﬁbrin deposition, reduced ﬁbrinolysis (increased concentrations of plasminogen activator inhibitor [PAI]-1)
and widening of the LSEC fenestrations lead to hepatic microvascular dysfunction/ischaemia and hepatocyte death. Increased expression of LSEC
adhesion molecules and chemoattractant mediator production (IL-8, platelet activating factor) promotes inﬂux of further immune eﬀector cells to mediate
hepatocyte death. Neutrophils (Nu) recruitment and activation occurs through TNF-a mediated chemokine production (e.g. macrophage inﬂammatory
protein [MIP]-2, macrophage chemotactic protein [MCP]-1). The release of reactive oxygen species (ROS), peroxynitrite and proteases from these
activated neutrophils induce intracellular hepatocyte oxidative stress and oncotic necrosis. [This ﬁgure appears in colour on the web.]
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death ligands and perforin release [129,132–134]
(Fig. 6). The role of NK/NKT cells in the development
of ALF in man needs to be explored.
8.3. Neutrophils
During acute liver injury, neutrophils are recruited to
hepatic sinusoids and also primed by an array of pro-
inﬂammatory mediators released by innate immune cells
(TNF-a, IL-1, platelet activating factor [PAF], IL-8
[135–139]) and by dying/dead hepatocytes (high mobil-
ity group box protein 1 [HMGB1, lipid peroxidation
products [140,141]). Mediators released from dying or
dead hepatocytes and CXC chemokines are very potent
at promoting neutrophil extravasation into the hepatic
parenchyma. Once within the hepatic parenchyma, neu-
trophils are fully activated and induce intracellular
hepatocyte stress and oncotic necrosis through the
release of ROIs and proteases [142]. Neutrophil-inducedhepatocyte injury has been implicated in ischaemia–
reperfusion [143,144], endotoxic shock [145,146], Con-
A [147] models of ALF.
8.4. Liver sinusoidal endothelial cells
The LSEC do not solely constitute a physical barrier
between the sinusoidal lumen and parenchyma, but
actively participate in acute liver injury in both hepatic
and systemic inﬂammatory conditions. A distinct func-
tion of such cells is their ability to clear pro-inﬂamma-
tory substances, such as LPS, from sinusoidal blood
without inducing widespread inﬂammation. This unique
ability is mediated through an enhanced production of
anti-inﬂammatory mediators (endogenous prostanoids
[148], TGF-b [113], IL-10 [111]), reduction in the expres-
sion of adhesion (ICAM/VCAM [114]) and antigen pre-
sentation/co-stimulator molecules (MHC class II,
CD80/86 [149]) during exposure to pro-inﬂammatory
mediators such as LPS.
IFN-γ
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 KC mϕ ϕ ϕ, N, , E , LSEC   
↑ chemokine production 
(eg.  MIP-2, MCP-1, IP-10, RANTES)
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↑ TRAIL 
Perforin secretion
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Fig. 6. Role of natural killer (NK) and natural killer T (NKT) cells in mediating acute liver injury. Following activation, NK and NKT cells promote
hepatocellular death and inﬂammation directly or via production of cytokines (IL-4, IL-5, IFN-c) and chemokines (macrophage inﬂammatory protein
[MIP]-2, monocyte chemotactic [MCP]-1, IFN-c inducible protein [IP]-10, regulated on activation normal T cell expressed and secreted [RANTES]).
Release of NK/NKT derived cytokines stimulates liver sinusoidal endothelial cells (LSEC), Kupﬀer cells (KC), neutrophils (Nu) and macrophages (mu),
to produce chemokines and adhesion molecules responsible for promoting inﬁltration of further immune eﬀector cells. More speciﬁcally, NK cell derived
IL-5 release recruits and activates eosinophils (Eu). Increased surface expression of death ligands (Fas ligand [FasL]), TNF-related apoptosis-induced
ligand [TRAIL]) and secretion of perforin from activated NK/NKT cells directly induce hepatocyte death. [This ﬁgure appears in colour on the web.]
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hepatic neutrophil recruitment in LPS/galactosamine-
induced ALF, the increased expression of the adhesion
molecule E-selectin, promotes neutrophil activation
and increases the expression of the adhesion glycopro-
tein Mac-1 (CD11b/CD18), that favours hepatic trans-
migration and neutrophil-dependent cytotoxicity
[138,145,150].
In this ALF model, TNF-a widens LSEC fenestra-
tions permitting direct contact of neutrophils with the
hepatic parenchyma, thereby promoting hepatocyte
injury. Platelet and red blood cell extravasation through
these fenestrations also contributes to hepatocyte death
through the induction of microcirculatory disturbances
and hepatic ischaemia [151].
Of note, activated LSEC participate in hepatocyte
injury during systemic endotoxaemia/sepsis. Circulating
TNF-a activates LSEC to produce chemoattractants,
such as IL-8 and PAF that lead to the increased expres-
sion of b-integrins (LFA-1 and Mac-1) on leucocytes,
initiating leucocyte transmigration into the hepatic
parenchyma and ensuing hepatocellular injury [152].
Early in polymicrobial sepsis, hepatic microvasculardysfunction occurs as a consequence of platelet activa-
tion, recruitment and adhesion to the hepatic sinusoidal
endothelium. This triggers a sequence of events that cul-
minate in leucocyte adhesion, sinusoidal ﬁbrin deposi-
tion and hepatocyte hypoxia/death [153–155].9. Hepatocyte apoptosis and immune dysregulation
Hepatocyte apoptosis has been documented in viral,
ischaemia/reperfusion, cholestatic and drug/toxin-
induced liver injury. In this section, we brieﬂy discuss
the engagement of signalling pathways that results in
hepatocyte apoptosis.
9.1. TNF- receptor mediated hepatocyte death
The pathogenic role of TNF-a has been extensively
documented, in experimental and human models of
acute liver failure, largely operating through hepatocyte
apoptosis [94,116–120,143,156–159]. TNF-a can also
stimulate hepatocyte proliferation and promote regener-
ation following partial hepatectomy [85]. The pleiotro-
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ulate both pro-(Fas-associated death domain, c-Jun
NH2-terminal kinase) and anti-apoptotic (NF-jB) sig-
nalling pathways following interaction with its hepato-
cyte receptor (TNF receptor) [98]. Factors tilting the
balance towards a pro- or anti-apoptotic outcome
remain to be elucidated. Hepatocyte sensitisation to
the pro-apoptotic eﬀects of TNF-a occurs when the
NF-jB survival signalling is suppressed, as reported in
the LPS/galactosamine model of ALF. Here, inhibition
of NF-jB with galactosamine, a liver-speciﬁc toxin, is
necessary to render the hepatocyte sensitive to the pro-
apoptotic eﬀects of TNF-a [116,118,158]. Other experi-
mental ALF models support the concept that the degree
of oxidative/intracellular stress determines whether or
not the hepatocyte will be sensitive to apoptosis follow-
ing TNF-a exposure [119].
9.2. Fas–Fas ligand (Fas–FasL) mediated hepatocyte
death
One mechanism by which hepatic macrophages and
NKT cells induce hepatocyte apoptosis is via the Fas–
FasL signalling pathway [160,161]. Fas is constitutively
expressed on hepatocyte membranes and is over-
expressed at the time of liver damage [162]. Both murine
and human studies of acute liver failure describe the
triggering of intracellular caspase-dependent signalling
pathways through Fas–FasL interaction, resulting in
hepatocyte apoptosis [160,162–164]. The pathogenic
role of this pathway has been conﬁrmed by reports that
depletion or silencing of Fas/FasL protects against mur-
ine acetaminophen-induced ALF [129,165].10. Potential immunomodulatory strategies in ALF
Given the complexity of innate immune responses
and cytokine networks in acute liver injury, several fac-
tors need to be evaluated when considering immuno-
modulating strategies.
10.1. Modulation of innate immune eﬀector cells
Inhibition of KC [106,107,127,166,167], NK/NKT
cell [129,130] and neutrophil [145,168,169] function can
attenuate the severity of acute liver injury in experimen-
tal ALF. A degree of redundancy exists whereby a single
hepatic insult can activate numerous eﬀector cells which
perform overlapping eﬀector functions resulting in hepa-
tocyte death. This is evident in acetaminophen-induced
ALF, where the inhibition of either KC/macrophage
[106,170] or NK/NKT [129] cell function can amelio-
rate, though not fully prevent, liver injury. Thus, inhibi-
tion of a single eﬀector cell type is unlikely to provide
the ‘‘magic bullet” to arrest completely liver injury.10.2. Modulation of cytokine networks
10.2.1. ‘‘Early” hepatotoxic stage
The cytokine milieu generated following a speciﬁc
liver insult is important when considering immunomod-
ulatory strategies. For example, immunodepletion of
IFN-c, but not TNF-a, ameliorates liver injury in acet-
aminophen-induced ALF [123,171,172], whereas inhibi-
tion of TNF-a is protective in both LPS/galactosamine
[116,118] and concanavalin-A induced ALF [120].
ALF models have shown that the early response to
liver injury involves simultaneous activation of both
pro- and anti-inﬂammatory mediators, the balance of
which determines the degree of liver injury incurred.
Studies have shown that IL-6 [173], IL-10 [91,95], IL-
15 [174], and prostaglandin E1 [175–177] are protective
at the onset of hepatic injury through modulation of
pro-inﬂammatory mediator release. However, the per-
sistence of an anti-inﬂammatory activity mediated by
IL-10 and TGF-b, may in fact impair hepatic recovery
at the later stages of acute hepatic injury [89].
10.2.2. ‘‘Late’’ regenerative stage
Following peak hepatotoxicity, the cytokine milieu
will alter in order to favour the resolution of acute
inﬂammation and promote regeneration. Numerous
cytokines (TNF-a [178,179], IL-6 [180,181]) and growth
factors (hepatocyte growth factor, epidermal growth
factor [85]) are implicated in hepatic regeneration. In
the partial hepatectomy model, the administration of
immunosuppressants (calcineurin inhibitors) in conjunc-
tion with an exogenous growth factor (e.g. G-CSF) may
‘‘tip” the balance towards the resolution of inﬂamma-
tion and promote hepatocyte regeneration [182–184].
10.2.3. Intracellular signalling pathways
Given the degree of pleiotropy of cytokine signalling
and immune eﬀector functions, a promising approach to
promote hepatocyte survival in acute liver injury may be
represented by the inhibition of intracellular signalling
pathways (c-jun terminal kinase [185]) and genes (Fas,
caspase 8) responsible for the induction of apoptosis.
This approach has been recently highlighted in murine
ALF where small interfering RNA ameliorated liver
injury through inhibition of Fas and capase 8 expression
[186,187].
10.2.4. Modulation of systemic inﬂammatory responses
A homeostatic response following acute hepatic
injury should comprise balanced and opposing pro-
and anti-inﬂammatory components, serving to limit
the extent of parenchymal damage and simultaneously
promoting tissue recovery, without lasting adverse
eﬀects to the host. However, this is not the case in
ALF, where a massive and uncontrolled activation of
the systemic inﬂammatory response, paralleled by an
856 C.G. Antoniades et al. / Journal of Hepatology 49 (2008) 845–861equally uncontrolled anti-inﬂammatory response, results
in progressive MODS. Recent work in ALF and non-
ALF conditions provides insights into the immunologi-
cal proﬁle prevailing in systemic inﬂammation. While in
the past only the pro-inﬂammatory component was con-
sidered, recent evidence, as discussed above, indicates
that the development and persistence of CARS, with
attendant functional monocyte deactivation, is inextri-
cably linked with enhanced susceptibility to sepsis and
death.
Further work is needed to identify the individual
immune components involved in the process, their rela-
tive contribution, functional relationship and evolution
over time in patients who survive and in those who do
not. Staging of the immune status during evolution of
disease and recognition of pro- or anti-inﬂammatory
predominance may provide experimental grounds on
which to base intervention with immunomodulatory
agents.Acknowledgements
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